89bio announces u.s. fda has granted breakthrough therapy designation for pegozafermin in nonalcoholic steatohepatitis (nash)

–supported by positive data in f2/f3 and f4 nash patients from the enliven phase 2b trial of pegozafermin– –discussions with regulatory agencies regarding the nash phase 3 program planned for the fourth quarter of 2023– san francisco, sept. 21, 2023 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the u.s. food and drug administration (fda) granted breakthrough therapy designation (btd) to pegozafermin in patients with nonalcoholic steatohepatitis (nash).
ETNB Ratings Summary
ETNB Quant Ranking